Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ranibizumab vs Aflibercept for Macular Edema in Young Adults with CRVO
NCT05282420Phase 4Unknown
- Sponsor
- South Valley University
- Start
- Feb 2021
- Primary completion
- Apr 2022
- Modality
- Antibody Fragments, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 4, randomised trial in macular edema comparing Ranibizumab group with Aflibercept group (2 arms). Primary endpoint: Best Corrected Visual Acuity at 12 months. Status: unknown.
02
Drugs
ranibizumabaflibercept
03
Conditions
macular edema
Beyond the preview
Go deeper on NCT05282420.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05282420.